Samsara BioCapital’s Astria Therapeutics ATXS Stock Holding History

Samsara BioCapital’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25,000	Closed	-$208K	–	42
2023 Q2	$208K	Hold	25,000	–	–	0.04%	42
2023 Q1	$333K	Hold	25,000	–	–	0.07%	44
2022 Q4	$372K	Hold	25,000	–	–	0.08%	47
2022 Q3	$226K	Hold	25,000	–	–	0.05%	52
2022 Q2	$75K	Hold	25,000	–	–	0.02%	55
2022 Q1	$168K	Hold	25,000	–	–	0.04%	56
2021 Q4	$135K	Hold	25,000	–	–	0.03%	50
2021 Q3	$221K	Hold	25,000	–	–	0.03%	47
2021 Q2	$317K	Hold	25,000	–	–	0.04%	49
2021 Q1	$434K	Sell	25,000 -25,000	-50%	-$452K	0.08%	43
2020 Q4	$642K	Hold	50,000	–	–	0.06%	41
2020 Q3	$1.86M	Hold	50,000	–	–	0.52%	29
2020 Q2	$1.93M	Hold	50,000	–	–	0.62%	25
2020 Q1	$1.25M	Hold	50,000	–	–	0.72%	23
2019 Q4	$1.77M	Hold	50,000	–	–	0.85%	19
2019 Q3	$1.62M	Hold	50,000	–	–	1.1%	13
2019 Q2	$2.42M	Hold	50,000	–	–	1.6%	13
2019 Q1	$2.38M	Hold	50,000	–	–	1.87%	12
2018 Q4	$1.31M	Buy	+50,000	New	+$1.89M	1.26%	12

Other funds holding ATXS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Samsara BioCapital's ATXS Position: Q3 2023 in Review

Samsara BioCapital sold out of Astria Therapeutics (ATXS) in Q3 2023, closing a stake of 25,000 shares — an estimated $208K sold.

Samsara BioCapital first reported a position in ATXS in Q4 2018 and held it in 19 quarters. The position peaked at $2.42M in Q2 2019. 68 funds tracked by Wall St. Rank hold ATXS as of Q3 2023.

Samsara BioCapital reported no remaining Astria Therapeutics position as of Q3 2023 after selling out during the quarter.
Samsara BioCapital sold 25,000 Astria Therapeutics shares in Q3 2023, an estimated $208K.
Samsara BioCapital first reported a position in Astria Therapeutics in Q4 2018 and held it in 19 quarters.
Samsara BioCapital's Astria Therapeutics position peaked at $2.42M in Q2 2019.
68 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2023.

Based on Samsara BioCapital's 13F filing for Q3 2023, filed 14 Nov 2023.